A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer

Clinical Cancer Research

Volumn 11, Issue 9, 2005, Pages 3342-3348

  Liao, Zhongxing ^a   Komaki, Ritsuko ^a   Milas, Luka ^a   Yuan, Chen ^b   Kies, Merrill ^a   Chang, Joe Y ^a   Jeter, Melenda ^a   Guerrero, Thomas ^a   Blumenschien, George ^a   Smith, Cheryl M ^a   Fossella, Frank ^a   Brown, Barry ^a   Cox, James D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Tongji Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; GEMCITABINE; IRINOTECAN; PACLITAXEL; WARFARIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ESOPHAGITIS; FATIGUE; FEMALE; HEMOPTYSIS; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION RESPONSE; RADIOSENSITIVITY; SIDE EFFECT; SKIN TOXICITY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; COMBINED MODALITY THERAPY; CYCLOOXYGENASE INHIBITORS; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGITIS; FATIGUE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PNEUMONIA; PROGNOSIS; PYRAZOLES; RADIOTHERAPY DOSAGE; SKIN DISEASES; SULFONAMIDES; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 20944447527     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1741     Document Type: Article

References (42)

1. American Cancer Society. Cancer facts and figures. Atlanta (GA): American Cancer Society; 2001.
2. Dillman RO, Herndon J, Seagren SL, Eaton WL, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-5.
3. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999;17:2692-9.
4. Salgia R, Skarin AT. Molecular abnormalities in lung cancer. J Clin Oncol 1998;16:1207-17.
5. Fong KM, Sekido Y, Minna JD. Molecular pathogenesis of lung cancer. J Thorac Cardiovasc Surg 1999;118: 1136-52.
6. 2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990;265:16737-40.
7. Liao Z, Komaki R, Mason K, Milas L. Role of cyclooxygenase-2 inhibitors in combination with radiation therapy in lung cancer. Clin Lung Cancer 2003;4:356-65.
8. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-4.
9. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001.
10. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999;5:1001-5.
11. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7:861-7.
12. Hanson WR. Eicosanoid-induced radioprotection and chemoprotection: laboratory studies and clinical applications. In: Bump EA, Malaker K, editors. Radioprotectors: chemical, biological and clinical perspectives. Boca Raton (FL): CRC Press; 1998. p. 197-221.
13. Milas L, Hanson W. Eicosanoids and radiation. Eur J Cancer 1995;31A:1580-85.
14. Raju U, Nakata E, Yang P, Newman RA, Ang KK, Milas L. In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations. Int J Radiat Oncol Biol Phys 2002;54:886-94.
15. Davis T, Hunter N, Trifan O, Milas L, Masferrer J. COX-2 inhibitors as radiosensitizing agents for cancer therapy. Am J Clin Oncol 2003;4:S58-61.
16. Pyo H, Choy H, Amorino GP, et al. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 2001;7:2998-3005.
17. Milas L, Kishi K, Hunter N, Mason K, Masferrer JL, Tofilon PJ. Enhancement: of tumor response to γ-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 1999;91:1501-4.
18. Kishi K, Petersen S, Petersen C, et al. Preferential enhancement of tumor radioresponse by cyclooxygenase-2 inhibitor. Cancer Res 2000;60:1326-31.
19. Petersen C, Petersen S, Milas L, Lang FF, Tofilon P. Human glioma cell radiosensitization by a selective COX-2 inhibitor. Clin Cancer Res 2000;6:2513-20.
20. Hida T, Kozaki K, Muramatsu H, et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000;6:2006-11.
21. Duffy C, Elliott C, O'Connor R, et al. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer 1998;34:1250-9.
22. Trifan OC, Durham WF, Salazar VS, et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 2002;62:5778-84.
23. Acute radiation morbidity scoring criteria; 2004. Available from: http://www.rtog.org/members/toxicity/acute.htm
24. O'Quigley J, Shen L. Continual reassessment method: a likelihood approach. Biometrics 1996;52:673-84.
25. Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy. Am J Clin Oncol 2003;26: S66-9.
26. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS Study: a randomized controlled trial. JAMA 2000;284:1247-55.
27. Cleland LG, James MJ, Stamp LK, Penglis PS. COX-2 inhibition and thrombotic tendency: a need for surveillance. Med J Aust 2001;175:214-7.
28. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
29. Burton J, Badine E, El-Sayah D, et al. Update of a phase I/II trial of carboplatin/gemcitabine plus escalating doses of celecoxib for first-line treatment of stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2004;22:7339 abstract.
30. Shehadeh N, Kalemkerian G, Wozniak A, et al. Preliminary results of a phase II study of celecoxib and weekly docetaxel in elderly (≥70 yes) or PS2 patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2003;22:686.
31. Gadgeel S, Thatai L, Kraut M, et al. Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy. Proc Am Soc Clin Oncol 2003;22: 684 (abstract 2749).
32. Nugent F, Graziano S, Levitan N, et al. Docetaxel and COX-2 inhibition with celecoxib in relapsed/refractoy non-small cell lung cancer (NSCLC): promising progression-free survival in a phase II study. Proc Am Soc Clin Oncol 2003;22:671 (abstract 2697).
33. Stani S, Carillio G, Meo S, et al. Phase II study of celecoxib and weekly paclitaxel in the treatment of pretreated advanced non-small cell lung cancer (NSVLC). J Clin Oncol 2004;22:145s (abstract 7337).
34. Keresztes RS, Socinski M, Bonomi P, Chen A, Hart L, Lilenbaum R. Phase II randomized trial of irinotecan/docetaxel (ID) or irinotecan/gemcitabine (IG) with or without celecoxib (CBX) in 2nd-line treatment of non-small-cell lung cancer (NSCLC). J Clin Oncol 2004;22:7137 abstract.
35. Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 2003;21:2645-50.
36. Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin Radiat Oncol 2001;11:290-9.
37. Liao Z, Milas L. COX-2 and its inhibition as a molecular target in the prevention and treatment of lung cancer. Expert Rev of Anticancer Ther 2004; 4:543-60.
38. Choy H, Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: A rational advance? J Natl Caner Inst 2003;95:1440-52.
39. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 2001;15:2057-72.
40. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-11.
41. Zweifel BS, Davis TW, Ornberg RL, Masferrer JL. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res 2002;62:6706-11.
42. Milas L, Hunter NR, Mason KA, Milross CG, Saito Y, Peters LJ. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res 1995;55:3564-68.